August 11, 2020 -- Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and manufacturing capabilities, in part due to COVID-19.
In total the company plans to invest over $2 billion in the two facilities, which will add 256-kiloliter capacity and begin manufacturing activities in the second half of 2022. The site will be the world's largest manufacturing facility at a single location. The plant will incorporate multiscale manufacturing by incorporating advantages from Samsung's three previous sites.
The 23.8 million sq m facility will incorporate real-time production schedule simulation with automation and the latest biomanufacturing technologies and utility supply-based optimization. The new site will contain streamlined application, smart disposal of high-concentration wastewater, and improvement of nitric acid emissions.
The company is also in negotiations with the authorities at the Incheon Free Economic Zone to purchase additional land for a second complex. This site is located near the company's current complex and will add 330,000 sq m of manufacturing space.